Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
38 studies found for:    Open Studies | "Alopecia"
Show Display Options
Rank Status Study
1 Recruiting A Study of Secukinumab for the Treatment of Alopecia Areata
Condition: Alopecia Areata
Interventions: Drug: Secukinumab;   Drug: Placebo
2 Recruiting Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Condition: Alopecia Areata
Interventions: Drug: Apremilast;   Drug: Placebo
3 Recruiting A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
Condition: Alopecia Areata
Interventions: Drug: Tralokinumab;   Drug: Placebo
4 Recruiting Topical Garlic Concentrate for Alopecia Areata in Children
Condition: Alopecia Areata
Intervention: Drug: garlic concentrate
5 Recruiting Excimer Light for Alopecia Areata
Condition: Alopecia Areata
Intervention: Procedure: UVB excimer light
6 Recruiting Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
Condition: Alopecia
Interventions: Drug: CG 428 cutaneous solution;   Drug: Placebo cutaneous solution
7 Recruiting Intralesional Steroids in the Treatment of Alopecia Areata
Condition: Alopecia Areata
Interventions: Drug: Intralesional Triamcinolone 2.5 mg/ml;   Drug: Intralesional Triamcinolone 5 mg/ml;   Drug: Intralesional Triamcinolone 10 mg/ml;   Drug: Intralesional Saline
8 Not yet recruiting Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
Condition: Androgenetic Alopecia
Interventions: Device: Autologous Platelet Rich Plasma;   Device: Saline solution injection
9 Recruiting Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Condition: Alopecia
Interventions: Drug: setipiprant;   Drug: placebo;   Drug: finasteride
10 Recruiting "Impact of Chemotherapy-induced Alopecia on the Quality of Life of Women With Breast Cancer"
Condition: Chemotherapy-induced Alopecia
Intervention: Behavioral: Semi-structured interviews
11 Not yet recruiting Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
Condition: Alopecia Areata
Interventions: Drug: PF-06651600;   Drug: PF-06700841;   Drug: Placebo
12 Not yet recruiting Safety and Efficacy Study of SHAPE Gel in Alopecia Areata
Condition: Alopecia Areata
Intervention: Drug: SHAPE Gel
13 Not yet recruiting Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia
Condition: Frontal Fibrosing Alopecia
Intervention: Other: Corticosteroid/Saline
14 Recruiting TREg Activation in the Treatment of the PELADE (Alopecia Areata)
Condition: Alopecia Areata
Interventions: Drug: IL2;   Drug: placebo
15 Recruiting Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia
Condition: Androgenetic Alopecia
Intervention: Device: topical 5% Minoxidil (Microneedling)
16 Recruiting Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
Condition: Alopecia, Androgenetic
Interventions: Drug: P-3074;   Drug: Finasteride;   Drug: Vehicle
17 Recruiting Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females
Condition: Alopecia Areata
Intervention: Other: MEXIS/M6S Patent - lotion against alopecia
18 Recruiting Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
Conditions: Alopecia;   Alopecia, Androgenetic;   Baldness
Intervention: Drug: Bimatoprost
19 Recruiting PAI-1 Expression in Non-scarring Hair Loss
Conditions: Androgenetic Alopecia;   Telogen Effluvium;   Alopecia Areata
Intervention:
20 Not yet recruiting Hairstetics™ Anchoring System in Female Pattern Hair Loss (HAS-FPHL)
Conditions: Female Pattern Baldness;   Alopecia, Androgenetic
Intervention: Device: Hairstetics™ anchoring system

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.